Currently there are no clinic or laboratory tests that can definitively diagnose a patient with Long COVID. However, symptoms such as myalgia or lingering cough are possible indicators of the condition. These symptoms may persist 4 to 6 weeks following a COVID-19 infection.
While many people can recover from COVID-19 in a few weeks, some continue to experience lingering symptoms that can last for months or even develop new or recurring symptoms later on. This condition can affect anyone who contracted COVID-19, regardless of the severity of their initial symptoms. It is also commonly known as “Long COVID,” and those who experience these prolonged symptoms are often referred to as “long-haulers.
As serious and intimidating the virus is, there are ways to dampen its effects. A key focus in doing so is the recovery of damaged organs. When the virus or its mimic antibodies cause muscle damage, it can lead to muscle pain and aches lasting 4 to 6 weeks after infection. This condition can be diagnosed as myalgia.
We utilize acupuncture and medicinal herbs to reduce inflammation, recover damaged muscle fibers, and prevent adhesions in the muscle fibers. This way we can effectively address myalgia and other similar symptoms. Myalgia is one symptom of long COVID that we treat with a high success rate. For more information, you can visit https://www.anmedicine.com and learn about the underlying mechanisms at https://www.anmedicine.thinkific.com.
Other Neuropsychiatric Symptoms Alongside Myalgia
Neuropsychiatric symptoms of Long COVID, including brain fog, inability to concentrate, and headache, have puzzled researchers and clinicians, who hunt for those symptoms’ causes. A new study found that neuroinflammation and blood-brain-barrier dysfunction are not likely drivers of the symptoms, giving researchers more clues in their quest to uncover what actually may be the culprit.
Scientists have proposed many potential causes of the neuropsychiatric symptoms—including damage of the blood vessels in the brain, ongoing brain inflammation, and lingering viral infection. This study is the first time researchers have tested a large cohort of people living with Long COVID for spinal fluid markers of brain inflammation and blood-brain-barrier dysfunction. The researchers published their findings in JAMA Network Open on November 10, and the outcome is significant even with the negative finding.
“Our study suggests that interventions that are aimed at quieting brain inflammation likely won’t help people with Long COVID,” says Shelli Farhadian, MD, PhD, assistant professor of medicine (infectious diseases) at Yale School of Medicine (YSM) and first author of the study. For many years, Farhadian and Serena Spudich, MD, Gilbert H. Glaser Professor of Neurology and senior author, have been studying neurological abnormalities caused by human immunodeficiency virus (HIV) infection. An important way to assess this is through cerebrospinal fluid (CSF), which offers a window into the brains of living people. “It’s the only part of the central nervous system that’s easily accessible,” says Farhadian. “It can and has already told us a lot about the brain and people living with other infections and inflammatory diseases like multiple sclerosis, HIV, and Parkinson’s disease.” Researchers can look at proteins and cells in the spinal fluid to see if there is any neurological dysfunction, including abnormal immune activity or blood-brain-barrier impairment.